Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 03 Jan 2019
At a glance
- Drugs Rovalpituzumab tesirine (Primary) ; Dexamethasone
- Indications Small cell lung cancer
- Focus Adverse reactions; Registrational
- Sponsors AbbVie
- 21 Dec 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 21 Dec 2018 Planned End Date changed from 19 Sep 2020 to 20 Dec 2018.
- 21 Dec 2018 Planned primary completion date changed from 19 Sep 2020 to 20 Dec 2018.